Meta-analysis: Pharmacologic treatment of obesity

Annals of Internal Medicine

Volumn 142, Issue 7, 2005, Pages 532-546

  Li, Zhaoping ^a   Maglione, Margaret ^b   Tu, Wenli ^b   Mojica, Walter ^b   Arterburn, David ^b   Shugarman, Lisa R ^b   Hilton, Lara ^b   Suttorp, Marika ^b   Solomon, Vanessa ^b   Shekelle, Paul G ^b   Morton, Sally C ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMFEPRAMONE; ANTIOBESITY AGENT; FLUOXETINE; PHENTERMINE; SERTRALINE; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TOPIRAMATE; ZONISAMIDE;

ABDOMINAL PAIN; ARTICLE; ASTHENIA; BLOATING; CLINICAL TRIAL; CONSTIPATION; DATA BASE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; FATIGUE; FLATULENCE; FOOD AND DRUG ADMINISTRATION; GALLBLADDER DISEASE; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; HYPERSOMNIA; HYPERTENSION; INSOMNIA; META ANALYSIS; NAUSEA AND VOMITING; NERVOUSNESS; NEUROTOXICITY; OBESITY; PARESTHESIA; POPULATION RESEARCH; PRIORITY JOURNAL; PRURITUS; RASH; RESPIRATORY TRACT DISEASE; RHINITIS; SIDE EFFECT; SOMNOLENCE; SWEATING; TACHYCARDIA; TASTE DISORDER; TREATMENT OUTCOME; TREMOR; UNITED STATES; URTICARIA; XEROSTOMIA; ADULT; CONTROLLED CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; WEIGHT REDUCTION;

ADULT; ANTI-OBESITY AGENTS; HUMANS; OBESITY; RANDOMIZED CONTROLLED TRIALS; WEIGHT LOSS;

EID: 15944367788     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-142-7-200504050-00012     Document Type: Article

References (102)

1. Bray GA, Greenway FL. Current and potential drugs for treatment of obesity. Endocr Rev. 1999;20:805-75.
2. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA. 2002;288:1723-7.
3. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. JAMA. 2001;286:1195-200.
4. Mokdad AH, Serdula MK, Dietz WH, Bowman BA, Marks JS, Koplan JP. The continuing epidemic of obesity in the United States [Letter]. JAMA. 2000;284:1650-1.
5. Mokdad AH, Serdula MK, Dietz WH, Bowman BA, Marks JS, Koplan JP. The spread of the obesity epidemic in the United States, 1991-1998. JAMA. 1999;282:1519-22.
6. Centers for Disease Control and Prevention. Obesity Epidemic Increases Dramatically in the United States. Atlanta, GA: Centers for Disease Control and Prevention; 2002.
7. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA. 1994;272:205-11.
8. Katzmarzyk PT. The Canadian obesity epidemic, 1985-1998. CMAJ. 2002;166:1039-40.
9. Katzmarzyk PT. Obesity in Canadian children [Letter]. CMAJ. 2001;164:1563-4; author reply 1564-5.
10. World Health Organization. Controlling the Global Obesity Epidemic. Geneva: World Health Organisation; 2002.
11. Friedrich MJ. Epidemic of obesity expands its spread to developing countries. JAMA. 2002;287:1382-6.
12. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA. 1999;282:1523-9.
13. Pi-Sunyer FX. Medical hazards of obesity. Ann Intern Med. 1993;119:655-60.
14. Williamson DF, Serdula MK, Anda RF, Levy A, Byers T. Weight loss attempts in adults: goals, duration, and rate of weight loss. Am J Public Health. 1992;82:1251-7.
15. Jeffery RW, Kelly KM, Rothman AJ, Sherwood NE, Boutelle KN. The weight loss experience: a descriptive analysis. Ann Behav Med. 2004;27:100-6.
16. Eckel RH, Krauss RM. American Heart Association call to action: obesity as a major risk factor for coronary heart disease. AHA Nutrition Committee. Circulation. 1998;97:2099-100.
17. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults - The Evidence Report. National Institutes of Health. Obes Res. 1998;6 Suppl 2:51S-209S.
18. Pi-Sunyer FX. A review of long-term studies evaluating the efficacy of weight loss in ameliorating disorders associated with obesity. Clin Ther. 1996;18:1006-35; discussion 1005.
19. Allison DB, Pi-Sunyer FX. Obesity treatment: examining the premises. Endocr Pract. 1995;1:353-64.
20. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625-38.
21. Huang Z, Hankinson SE, Colditz GA, Stampfer MJ, Hunter DJ, Manson JE, et al. Dual effects of weight and weight gain on breast cancer risk. JAMA. 1997;278:1407-11.
22. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord. 1992;16:397-415.
23. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
24. Bray GA, Hollander P, Klein S, Kushner R, Levy B, Fitchet M, et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res. 2003;11:722-33.
25. Sibutramine. MedlinePlus.com. Available at www.nlm.nih.gov/medlineplus /druginfo/medmaster/a601110.html.
26. Sertraline. MedlinePlus.com. Available at www.nlm.nih.gov/medlineplus /druginfo/medmaster/a697048.html.
27. Nielsen JA, Chapin DS, Johnson JL Jr, Torgersen LK. Sertraline, a serotonin-uptake inhibitor, reduces food intake and body weight in lean rats and genetically obese mice. Am J Clin Nutr. 1992;55:185S-189S.
28. History of phentermine. Phentermine.com. Accessed at www.phentermine.com/ phentermine_history.htm on 4 May 2004.
29. Description: Tenuate (Diethylpropion Hydrochloride USP). RxList.com. Accessed at www.rxlist.com/cgi/generic3/diethprop.htm on 4 May 2004.
30. Drugs Approved by the FDA: Drug Name Zonegrin (Zonisamide) Capsules. Thompson CenterWatch Clinical Trials Listing Service. Accessed at www.centerwatch.com/patient/drugs/dru613.html on 4 May 2004.
31. Woods TM, Eichner SF, Franks AS. Weight gain mitigation with topiramate in mood disorders. Ann Pharmacother. 2004;38:887-91.
32. Topiramate. MedlinePlus.com. Available at www.nlm.nih.gov/medlineplus/ druginfo/medmaster/a697012.html.
33. Xenical (orlistat). Complete product information. Roche Pharmaceuticals. Available at www.rocheusa.com/products/xenical/pi.pdf.
34. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12.
35. Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med. 2004;164:994-1003.
36. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88.
37. Hedges LV, Olkin I. Statistical Methods for Meta-Analysis. San Diego, CA: Academic Pr; 1985.
38. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539-58.
39. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088-101.
40. Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med. 1999;106:179-84.
41. Hauner H, Meier M, Wendland G, Kurscheid T, Lauterback KW. Weight reduction by sibutramine in obese subjects in primary care medicine: the S.A.T. study [Abstract]. Int J Obes Relat Metab Disord. 2000;24:S100.
42. McNulty SJ, Ur E, Williams G. A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diabetes Care. 2003;26:125-31.
43. Smith IG, Goulder MA. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract. 2001;50:505-12
44. Wirth A, Krause J. Long-term weight loss with sibutramine: a randomized controlled trial. JAMA. 2001;286:1331-9.
45. Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med. 2000;9:160-7.
46. Hill JO, Hauptman J, Anderson JW, Fujioka K, O'Neil PM, Smith DK, et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. Am J Clin Nutr. 1999;69:1108-16.
47. Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care. 1998;21:1288-94.
48. Rossner S, Sjostrom L, Noack R, Meinders AE, Noseda G. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res. 2000;8:49-61.
49. Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet. 1998;352:167-72.
50. Vidgren HM, Agren JJ, Valve RS, Karhunen LJ, Rissanen AM, Uusitupa MI. The effect of orlistat on the fatty acid composition of serum lipid fractions in obese subjects. Clin Pharmacol Ther. 1999;66:315-22.
51. Rissanen P, Vahtera E, Krusius T, Uusitupa M, Rissanen A. Weight change and blood coagulability and fibrinolysis in healthy obese women. Int J Obes Relat Metab Disord. 2001;25:212-8.
52. Broom I. Randomised trial of the effect of orlistat on body weight and CVD risk profile in overweight and obese patients with co-morbidities [Abstract]. Int J Obes. 2001;25 Suppl:S106.
53. Muls E, Kolanowski J, Scheen A, Van Gaal L. The effects of otlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Int J Obes Relat Metab Disord. 2001;25:1713-21.
54. Deerochanawong C. Effect of treatment with orlistat in overweight or obese Thai patients with type 2 diabetes [Abstract]. Diabetes. 2001;50:A433.
55. Shi Yi F, Zhu Jun R. Effect of orlistat on weight loss and glycemic control in overweight Chinese patients with type 2 diabetes [Abstract]. Diabetes. 2001;50:A101-A102.
56. Kelley DE, Bray GA, Pi-Sunyer FX, Klein S, Hill J, Miles J, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial. Diabetes Care. 2002;25:1033-41.
57. Karhunen L, Franssila-Kallunki A, Rissanen P, Valve R, Kolehmainen M, Rissanen A, et al. Effect of orlistat treatment on body composition and resting energy expenditure during a two-year weight-reduction programme in obese Finns. Int J Obes Relat Metab Disord. 2000;24:1567-72.
58. Krempf M, Louvet JP, Allanic H, Miloradovich T, Joubert JM, Attali JR. Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity. Int J Obes Relat Metab Disord. 2003;27:591-7.
59. Halpern A, Mancini MC, Suplicy H, Zanella MT, Repetto G, Gross J, et al. Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients. Diabetes Obes Metab. 2003;5:180-8.
60. Lucas CP, Boldrin MN, Reaven GM. Effect of orlistat added to diet (30% of calories from fat) on plasma lipids, glucose, and insulin in obese patients with hypercholesterolemia. Am J Cardiol. 2003;91:961-4.
61. Bakris G, Calhoun D, Egan B, Hellmann C, Dolker M, Kingma I, et al. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. J Hypertens. 2002;20:2257-67.
62. Hanefeld M, Sachse G. The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab. 2002;4:415-23.
63. Miles JM, Leiter L, Hollander P, Wadden T, Anderson JW, Doyle M, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care. 2002;25:1123-8.
64. Rosenfalck AM, Hendel H, Rasmussen MH, Almdal T, Anderson T, Hilsted J, et al. Minor long-term changes in weight have beneficial effects on insulin sensitivity and beta-cell function in obese subjects. Diabetes Obes Metab. 2002;4:19-28.
65. Naumov VG, Lupanov VP, Dotsenko IuV, Tvorogova MG. [Six-month xenical (orlistat) therapy of patients with stable angina pectoris concomitant with obesity and hyperlipidemia]. Ter Arkh. 2002;74:47-51.
66. Gotfredsen A, Westergren Hendel H, Andersen T. Influence of orlistat on bone turnover and body composition. Int J Obes Relat Metab Disord. 2001;25:1154-60.
67. Reaven G, Segal K, Hauptman J, Boldrin M, Lucas C. Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X. Am J Cardiol. 2001;87:827-31.
68. Micic D, Ivkovic-Lazar T, Dragojevic R, Jorga J, Stokic E, Hajdukovic Z. Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia. Med Pregl. 1999;52:323-33.
69. Derosa G, Mugellini A, Ciccarelli L, Fogari R. Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet. Clin Ther. 2003;25:1107-22.
70. Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA. 1999;281:235-42.
71. Lindgarde F. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. J Intern Med. 2000;248:245-54.
72. Broom I, Wilding J, Stott P, Myers N. Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study. Int J Clin Pract. 2002;56:494-9.
73. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study, a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155-61.
74. Haddock CK, Poston WS, Dill PL, Foreyt JP, Ericsson M. Pharmacothetapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord. 2002;26:262-73.
75. Kokkinos J, Levine SR. Possible association of ischemic stroke with phentermine. Stroke. 1993;24:310-3.
76. Kim I, Whitsett TL. Acute vasospasm associated with anorexiant use. J Okla State Med Assoc. 1988;81:395-8.
77. Thomson Healthcare Products. Micromedex Healthcare Series. Accessed at www.micromedex.com/products/hcs/ on 8 December 2004.
78. Goldstein DJ, Rampey AH Jr, Enas GG, Potvin JH, Fludzinski LA, Levine LR. Fluoxetine: a randomized clinical trial in the treatment of obesity. Int J Obes Relat Metab Disord. 1994;18:129-35.
79. Marcus MD, Wing RR, Ewing L, Kern E, McDermott M, Gooding W. A double-blind, placebo-controlled trial of fluoxetine plus behavior modification in the treatment of obese binge-eaters and non-binge-eaters. Am J Psychiatry. 1990;147:876-81.
80. Darga LL, Carroll-Michals L, Botsford SJ, Lucas CP. Fluoxetine's effect on weight loss in obese subjects. Am J Clin Nutr. 1991;54:321-5.
81. O'Kane M, Wiles PG, Wales JK. Fluoxetine in the treatment of obese type 2 diabetic patients. Diabet Med. 1994;11:105-10.
82. Michelson D, Amsterdam JD, Kim Y, Sundell K. Changes in weight during a one-year trial with fluoxetine [Abstract]. Presented at 152nd Annual Meeting of the American Psychiatric Association, Washington, DC, 15-20 May 1999.
83. Connolly VM, Gallagher A, Kesson CM. A study of fluoxetine in obese elderly patients with type 2 diabetes. Diabet Med. 1995;12:416-8.
84. Mendoza Espejo R, Diaz Perez de Madrid J, Buitrago F. [Effectiveness of serotonergic agonists in the treatment of obese patients]. Aten Primaria. 1995;16:364-6.
85. Gray DS, Fujioka K, Devine W, Bray GA. Fluoxetine treatment of the obese diabetic. Int J Obes Relat Metab Disord. 1992;16:193-8.
86. Breum L, Bjerre U, Bak JF, Jacobsen S, Astrup A. Long-term effects of fluoxetine on glycemic control in obese patients with non-insulin-dependent diabetes mellitus or glucose intolerance: influence on muscle glycogen synthase and insulin receptor kinase activity. Metabolism. 1995;44:1570-6.
87. Anderson JW, Greenway FL, Fujioka K, Gadde KM, McKenney J, O'Neil PM. Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes Res. 2002;10:633-41.
88. Croft H, Houser TL, Jamerson BD, Leadbetter R, Bolden-Watson C, Donahue R, et al. Effect on body weight of bupropion sustained-release in patients with major depression treated for 52 weeks. Clin Ther. 2002;24:662-72.
89. Jain AK, Kaplan RA, Gadde KM, Wadden TA, Allison DB, Brewer ER, et al. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. Obes Res. 2002;10:1049-56.
90. Wadden TA, Bartlett SJ, Foster GD, Greenstein RA, Wingate BJ, Stunkard AJ, et al. Sertraline and relapse prevention training following treatment by very-low-calorie diet: a controlled clinical trial. Obes Res. 1995;3:549-57.
91. Anderson JW, Greenway F, Fujioka K, Gadde K, Mckenney J, O'Neill P. Bupropion SR significantly enhances weight loss when used with a moderate-intensity lifestyle intervention [Abstract]. Diabetes. 2001;50:A21.
92. Gilliam FG, Veloso F, Bomhof MA, Gazda SK, Biton V, Ter Bruggen JP, et al. A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy. Neurology. 2003;60:196-202.
93. Bray G, Klein S, Levy B, Fitchet M, and Perry B. Topiramate produces dose-related weight loss in obese patients [Abstract]. Presented at the 62nd Scientific Sessions of the American Diabetes Association Scientific Sessions, San Francisco, California, 14-18 June 2002.
94. Stenlof K, Rossner S, Vercruysse F, Perry B, Fitchet M, Sjostrom L. Safety and efficacy of topiramate in the treatment of Type II diabetic obese subjects: a randomized, double-blind, placebo-controlled trial [Abstract]. Presented at the 18th International Diabetes Federation Congress, Paris, France, 24-29 August 2003.
95. Stenlof K, Rossner S, Vercruysse F, Perry B, Fitchet M, Sjostrom L. Topiramate decreases weight and blood pressure in obese subjects with Type II diabetes [Abstract]. Presented at the North American Association for the Study of Obesity 2003 Annual Scientific Meeting, Fort Lauderdale, Florida, 11-15 October 2003.
96. Rissanen A, Wilding J, Van Gaal L, Vercruysse F, Perry B, Fitchet M. The effect of topiramate on body weight and blood pressure in obese subjects: a long-term, randomized, placebo-controlled trial [Abstract]. Presented at the 18th Internation Diabetes Federation Congress, Paris, France, 24-29 August 2003.
97. Pud'homme D, Firchet M, Almeras N, Dumont M, Tremblay A, Despres JP. Six-month topiramate treatment reduces body weight and blood pressure [Abstract]. Presented at the North American Association for the Study of Obesity 2003 Annual Scientific Meeting, Fort Lauderdale, Florida, 11-15 October 2003.
98. Tonstad S, Levy B, Perry B, Fitchet M. Topiramate decreases weight and lowers blood pressure in obese subjects with hypertension [Abstract]. Presented at the North American Association for the Study of Obesity 2003 Annual Scientific Meeting, Fort Lauderdale, Florida, 11-15 October 2003.
99. Caterson I, Astrup A, Zelissen P, Guy-Grand B, Carruba M, Levy B, et al. The long-term effect of topiramate on body weight maintenance after low-calorie diet-induced weight loss in obese subjects [Abstract]. Presented at the 18th International Diabetes Federation Congress, Paris, France, 24-29 August 2003.
100. Gadde KM, Franciscy DM, Wagner HR 2nd, Krishnan KR. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA. 2003;289:1820-5.
101. Gokcel A, Gumurdulu Y, Karakose H, Melek Ertorer E, Tanaci N, Bascil Tutuncu N, et al. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diabetes Obes Metab. 2002;4:49-55.
102. Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Arnold ME, Steinberg CM. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial. Obes Res. 2000;8:431-7.